메뉴 건너뛰기




Volumn 2, Issue 12, 2013, Pages 1-8

Vaccine therapy for pancreatic cancer

Author keywords

Cancer vaccine; Clinical trials; Immune checkpoint; Immunotherapy; Pancreatic cancer

Indexed keywords

ALGENPANTUCEL L; ALPHA INTERFERON; B7 ANTIGEN; BACTERIAL VACCINE; CARCINOEMBRYONIC ANTIGEN; CD86 ANTIGEN; CHOLECYSTOKININ B RECEPTOR; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; FLUOROURACIL; GASTRIN; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 96 VACCINE; HLA A2 ANTIGEN; IPILIMUMAB; K RAS PROTEIN; MUCIN 1; PEPTIDE VACCINE; RECOMBINANT VACCINE; SURVIVIN; TELOMERASE; TERTOMOTIDE; UNCLASSIFIED DRUG; VACCINIA VACCINE;

EID: 84894526058     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26662     Document Type: Article
Times cited : (52)

References (48)
  • 1
    • 33947313964 scopus 로고    scopus 로고
    • American Cancer Society
    • Cancer Facts & Figures 2012. Atlanta: American Cancer Society;
    • American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.
    • (2012)
  • 2
    • 33645527163 scopus 로고    scopus 로고
    • Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States)
    • Cancer Causes Control PMID:16596292
    • Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 2006; 17:403-9; PMID:16596292; http://dx.doi.org/10.1007/s10552-005-0539-4
    • (2006) , vol.17 , pp. 403-409
    • Cress, R.D.1    Yin, D.2    Clarke, L.3    Bold, R.4    Holly, E.A.5
  • 5
    • 77950544638 scopus 로고    scopus 로고
    • Chemoradiation in pancreatic adenocarcinoma: a literature review
    • PMID:20203172
    • Roy R, Maraveyas A. Chemoradiation in pancreatic adenocarcinoma: a literature review. Oncologist 2010; 15:259-69; PMID:20203172; http://dx.doi.org/10.1634/theoncologist.2009-0272
    • (2010) Oncologist , vol.15 , pp. 259-269
    • Roy, R.1    Maraveyas, A.2
  • 7
    • 33846405332 scopus 로고    scopus 로고
    • Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial
    • PMID:17227978
    • Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267-77; PMID:17227978; http://dx.doi.org/10.1001/jama.297.3.267
    • (2007) JAMA , vol.297 , pp. 267-277
    • Oettle, H.1    Post, S.2    Neuhaus, P.3    Gellert, K.4    Langrehr, J.5    Ridwelski, K.6    Schramm, H.7    Fahlke, J.8    Zuelke, C.9    Burkart, C.10
  • 8
    • 16844379997 scopus 로고    scopus 로고
    • Immunosuppressive networks in the tumour environment and their therapeutic relevance
    • PMID:15776005
    • Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74; PMID:15776005; http://dx.doi.org/10.1038/nrc1586
    • (2005) Nat Rev Cancer , vol.5 , pp. 263-274
    • Zou, W.1
  • 9
    • 0347505003 scopus 로고    scopus 로고
    • CD28-mediated co-stimulation: a quantitative support for TCR signalling
    • PMID:14647476;
    • Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003; 3:939-51; PMID:14647476; http://dx.doi.org/10.1038/nri124810.
    • (2003) Nat Rev Immunol , vol.3 , pp. 939-951
    • Acuto, O.1    Michel, F.2
  • 10
    • 33645018929 scopus 로고    scopus 로고
    • Prospects for vaccine therapy for pancreatic cancer
    • PMID:16549329
    • Gaudernack G. Prospects for vaccine therapy for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20:299-314; PMID:16549329;http://dx.doi.org/10.1016/j.bpg.2006.01.003
    • (2006) Best Pract Res Clin Gastroenterol , vol.20 , pp. 299-314
    • Gaudernack, G.1
  • 11
    • 13344270400 scopus 로고    scopus 로고
    • Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study
    • PMID:8621226;65:4<450::AIDIJC10> 3.0.CO;2-E
    • Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Gedde-Dahl T III, Stokke KT III, Sølheim BG, Egge TS, Søreide O, Thorsby E, et al. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 1996; 65:450-3; PMID:8621226; http://dx.doi.org/10.1002/(SICI)1097-0215(19960208)65:4<450::AIDIJC10>3.0.CO;2-E
    • (1996) Int J Cancer , vol.65 , pp. 450-453
    • Gjertsen, M.K.1    Bakka, A.2    Breivik, J.3    Saeterdal, I.4    Gedde-Dahl III, T.5    Stokke III, K.T.6    Sølheim, B.G.7    Egge, T.S.8    Søreide, O.9    Thorsby, E.10
  • 12
    • 0028856743 scopus 로고
    • Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation
    • PMID:7475823
    • Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Solheim BG, Søreide O, Thorsby E, Gaudernack G. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 1995; 346:1399-400; PMID:7475823; http://dx.doi.org/10.1016/S0140-6736(95)92408-6
    • (1995) Lancet , vol.346 , pp. 1399-1400
    • Gjertsen, M.K.1    Bakka, A.2    Breivik, J.3    Saeterdal, I.4    Solheim, B.G.5    Søreide, O.6    Thorsby, E.7    Gaudernack, G.8
  • 13
    • 0035342594 scopus 로고    scopus 로고
    • Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma
    • PMID:11291084
    • Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Søreide O, Eriksen JA, Møller M, Baksaas I, Lothe RA, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001; 92:441-50; PMID:11291084; http://dx.doi.org/10.1002/ijc.1205
    • (2001) Int J Cancer , vol.92 , pp. 441-450
    • Gjertsen, M.K.1    Buanes, T.2    Rosseland, A.R.3    Bakka, A.4    Gladhaug, I.5    Søreide, O.6    Eriksen, J.A.7    Møller, M.8    Baksaas, I.9    Lothe, R.A.10
  • 15
    • 33845247353 scopus 로고    scopus 로고
    • Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study
    • PMID:17060934
    • Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, Buanes T, Gaudernack G. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 2006; 95:1474-82; PMID:17060934; http://dx.doi.org/10.1038/sj.bjc.6603437
    • (2006) Br J Cancer , vol.95 , pp. 1474-1482
    • Bernhardt, S.L.1    Gjertsen, M.K.2    Trachsel, S.3    Møller, M.4    Eriksen, J.A.5    Meo, M.6    Buanes, T.7    Gaudernack, G.8
  • 16
    • 84877913638 scopus 로고    scopus 로고
    • Immunotherapy updates in pancreatic cancer: are we there yet?
    • PMID:23323149
    • Gunturu KS, Rossi GR, Saif MW. Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol 2013; 5:81-9; PMID:23323149; http://dx.doi.org/10.1177/1758834012462463
    • (2013) Ther Adv Med Oncol , vol.5 , pp. 81-89
    • Gunturu, K.S.1    Rossi, G.R.2    Saif, M.W.3
  • 17
    • 0034967512 scopus 로고    scopus 로고
    • Differential expression of gastrin, cholecystokinin-A and cholecystokinin-B receptor mRNA in human pancreatic cancer cell lines
    • PMID:11444473
    • Monstein HJ, Ohlsson B, Axelson J. Differential expression of gastrin, cholecystokinin-A and cholecystokinin-B receptor mRNA in human pancreatic cancer cell lines. Scand J Gastroenterol 2001; 36:738-43; PMID:11444473; http://dx.doi. org/10.1080/003655201300192003
    • (2001) Scand J Gastroenterol , vol.36 , pp. 738-743
    • Monstein, H.J.1    Ohlsson, B.2    Axelson, J.3
  • 18
    • 84859102950 scopus 로고    scopus 로고
    • An international multicenterrandomized controlled trial of G17DT in patients with pancreatic cancer
    • Gilliam AD, Broome P, Topuzov EG, Garin AM, Pulay I, Humphreys J, et al. An international multicenterrandomized controlled trial of G17DT in patients with pancreatic cancer. Pancrea. 2012; 41:374-9; http://dx.doi.org/10.1097/MPA.0b013e31822ade7e
    • (2012) Pancrea , vol.41 , pp. 74-79
    • Gilliam, A.D.1    Broome, P.2    Topuzov, E.G.3    Garin, A.M.4    Pulay, I.5    Humphreys, J.6
  • 19
    • 0035878930 scopus 로고    scopus 로고
    • Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors
    • PMID:11466679;92:2<271::AIDCNCR1319> 3.0.CO;2-0
    • Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001; 92:271-8; PMID:11466679; http://dx.doi.org/10.1002/1097-0142(20010715)92:2<271::AIDCNCR1319> 3.0.CO;2-0
    • (2001) Cancer , vol.92 , pp. 271-278
    • Satoh, K.1    Kaneko, K.2    Hirota, M.3    Masamune, A.4    Satoh, A.5    Shimosegawa, T.6
  • 20
    • 33745593715 scopus 로고    scopus 로고
    • Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin
    • PMID:16315030;
    • Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006; 55:1294-8; PMID:16315030; http://dx.doi.org/10.1007/s00262-005-0102-x
    • (2006) Cancer Immunol Immunother , vol.55 , pp. 1294-1298
    • Wobser, M.1    Keikavoussi, P.2    Kunzmann, V.3    Weininger, M.4    Andersen, M.H.5    Becker, J.C.6
  • 21
    • 84872277773 scopus 로고    scopus 로고
    • Immunotherapeutic benefit of α-interferon (IFNα) in survivin2Bderived peptide vaccination for advanced pancreatic cancer patients
    • PMID:23078230
    • Kameshima H, Tsuruma T, Kutomi G, Shima H, Iwayama Y, Kimura Y, Imamura M, Torigoe T, Takahashi A, Hirohashi Y, et al. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2Bderived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci 2013; 104:124-9; PMID:23078230; http://dx.doi.org/10.1111/cas.12046
    • (2013) Cancer Sci , vol.104 , pp. 124-129
    • Kameshima, H.1    Tsuruma, T.2    Kutomi, G.3    Shima, H.4    Iwayama, Y.5    Kimura, Y.6    Imamura, M.7    Torigoe, T.8    Takahashi, A.9    Hirohashi, Y.10
  • 22
    • 34347380750 scopus 로고    scopus 로고
    • A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma
    • PMID:17420942
    • Maki RG, Livingston PO, Lewis JJ, Janetzki S, Klimstra D, Desantis D, Srivastava PK, Brennan MF. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci 2007; 52:1964-72; PMID:17420942; http://dx.doi.org/10.1007/s10620-006-9205-2
    • (2007) Dig Dis Sci , vol.52 , pp. 1964-1972
    • Maki, R.G.1    Livingston, P.O.2    Lewis, J.J.3    Janetzki, S.4    Klimstra, D.5    Desantis, D.6    Srivastava, P.K.7    Brennan, M.F.8
  • 24
    • 38049089743 scopus 로고    scopus 로고
    • Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy
    • PMID:18197807;
    • Arlen PM, Gulley JL, Madan RA, Hodge JW, Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol 2007; 27:451-62; PMID:18197807; http://dx.doi.org/10.1615/CritRevImmunol.v27.i5.40
    • (2007) Crit Rev Immunol , vol.27 , pp. 451-462
    • Arlen, P.M.1    Gulley, J.L.2    Madan, R.A.3    Hodge, J.W.4    Schlom, J.5
  • 25
    • 0024741693 scopus 로고
    • Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes
    • PMID:2507553
    • Tilney LG, Portnoy DA. Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes. J Cell Biol 1989; 109:1597-608; PMID:2507553; http://dx.doi.org/10.1083/jcb.109.4.1597
    • (1989) J Cell Biol , vol.109 , pp. 1597-1608
    • Tilney, L.G.1    Portnoy, D.A.2
  • 28
    • 51349108306 scopus 로고    scopus 로고
    • Promises and challenges for the development of Listeria monocytogenes-based immunotherapies
    • PMID:18767955
    • Brockstedt DG, Dubensky TW. Promises and challenges for the development of Listeria monocytogenes-based immunotherapies. Expert Rev Vaccines 2008; 7:1069-84; PMID:18767955; http://dx.doi.org/10.1586/14760584.7.7.1069
    • (2008) Expert Rev Vaccines , vol.7 , pp. 1069-1084
    • Brockstedt, D.G.1    Dubensky, T.W.2
  • 30
    • 84856519280 scopus 로고    scopus 로고
    • A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction
    • PMID:22147941
    • Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2012; 18:858-68; PMID:22147941; http://dx.doi.org/10.1158/1078-0432.CCR-11-2121
    • (2012) Clin Cancer Res , vol.18 , pp. 858-868
    • Le, D.T.1    Brockstedt, D.G.2    Nir-Paz, R.3    Hampl, J.4    Mathur, S.5    Nemunaitis, J.6    Sterman, D.H.7    Hassan, R.8    Lutz, E.9    Moyer, B.10
  • 31
    • 68149088312 scopus 로고    scopus 로고
    • A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors
    • PMID:19129927
    • Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, Geller BA, Schmotzer A, Potter DP, Whiteside T, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008; 6(B):955-64; PMID:19129927
    • (2008) Cancer Ther , vol.6 , Issue.B , pp. 955-964
    • Lepisto, A.J.1    Moser, A.J.2    Zeh, H.3    Lee, K.4    Bartlett, D.5    McKolanis, J.R.6    Geller, B.A.7    Schmotzer, A.8    Potter, D.P.9    Whiteside, T.10
  • 32
    • 84857911626 scopus 로고    scopus 로고
    • Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/ or S-1 in patients with advanced pancreatic carcinoma
    • PMID:21792083
    • Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S, et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/ or S-1 in patients with advanced pancreatic carcinoma. Pancreas 2012; 41:195-205; PMID:21792083; http://dx.doi.org/10.1097/MPA.0b013e31822398c6
    • (2012) Pancreas , vol.41 , pp. 195-205
    • Kimura, Y.1    Tsukada, J.2    Tomoda, T.3    Takahashi, H.4    Imai, K.5    Shimamura, K.6    Sunamura, M.7    Yonemitsu, Y.8    Shimodaira, S.9    Koido, S.10
  • 33
    • 0027538181 scopus 로고
    • Vaccination with irradiated tumor cells engineered to secrete murine granulocytemacrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
    • PMID:8097319
    • Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocytemacrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90:3539-43; PMID:8097319; http://dx.doi.org/10.1073/pnas.90.8.3539
    • (1993) Proc Natl Acad Sci U S A , vol.90 , pp. 3539-3543
    • Dranoff, G.1    Jaffee, E.2    Lazenby, A.3    Golumbek, P.4    Levitsky, H.5    Brose, K.6    Jackson, V.7    Hamada, H.8    Pardoll, D.9    Mulligan, R.C.10
  • 34
    • 0035152718 scopus 로고    scopus 로고
    • Novel allogeneic granulocyte-macrophage colony-stimulating factorsecreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation
    • PMID:11134207
    • Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factorsecreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19:145-56; PMID:11134207
    • (2001) J Clin Oncol , vol.19 , pp. 145-156
    • Jaffee, E.M.1    Hruban, R.H.2    Biedrzycki, B.3    Laheru, D.4    Schepers, K.5    Sauter, P.R.6    Goemann, M.7    Coleman, J.8    Grochow, L.9    Donehower, R.C.10
  • 35
    • 40949157885 scopus 로고    scopus 로고
    • Allogeneic granulocyte macrophage colonystimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation
    • PMID:18316569
    • Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, et al. Allogeneic granulocyte macrophage colonystimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008; 14:1455-63; PMID:18316569; http://dx.doi.org/10.1158/1078-0432.CCR-07-0371
    • (2008) Clin Cancer Res , vol.14 , pp. 1455-1463
    • Laheru, D.1    Lutz, E.2    Burke, J.3    Biedrzycki, B.4    Solt, S.5    Onners, B.6    Tartakovsky, I.7    Nemunaitis, J.8    Le, D.9    Sugar, E.10
  • 36
    • 79151486551 scopus 로고    scopus 로고
    • A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation
    • PMID:21217520
    • Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011; 253:328-35; PMID:21217520; http://dx.doi.org/10.1097/SLA.0b013e3181fd271c
    • (2011) Ann Surg , vol.253 , pp. 328-335
    • Lutz, E.1    Yeo, C.J.2    Lillemoe, K.D.3    Biedrzycki, B.4    Kobrin, B.5    Herman, J.6    Sugar, E.7    Piantadosi, S.8    Cameron, J.L.9    Solt, S.10
  • 37
    • 84887069029 scopus 로고    scopus 로고
    • Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer
    • abstr 4040
    • Le DT, Wang-Gillam A, Picozzi VJ, Greten TF, Crocenzi TS, Gregory M, et al. Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer. J Clin Oncol 2013; 31, (suppl; abstr 4040)
    • (2013) J Clin Oncol , vol.31 , Issue.SUPPL.
    • Le, D.T.1    Wang-Gillam, A.2    Picozzi, V.J.3    Greten, T.F.4    Crocenzi, T.S.5    Gregory, M.6
  • 39
    • 0032812487 scopus 로고    scopus 로고
    • Progress in cancer genetics: lessons from pancreatic cancer
    • PMID:10436774;
    • Goggins M, Kern SE, Offerhaus JA, Hruban RH. Progress in cancer genetics: lessons from pancreatic cancer. Ann Oncol 1999; 10(Suppl 4):4-8; PMID:10436774; http://dx.doi.org/10.1093/annonc/10.suppl_4.S4
    • (1999) Ann Oncol , vol.10 , Issue.SUPPL 4 , pp. 4-8
    • Goggins, M.1    Kern, S.E.2    Offerhaus, J.A.3    Hruban, R.H.4
  • 44
    • 84876807399 scopus 로고    scopus 로고
    • Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma
    • PMID:23622132
    • Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology 2013; 144:1230-40; PMID:23622132; http://dx.doi.org/10.1053/j.gastro.2012.12.042
    • (2013) Gastroenterology , vol.144 , pp. 1230-1240
    • Zheng, L.1    Xue, J.2    Jaffee, E.M.3    Habtezion, A.4
  • 45
    • 77958050577 scopus 로고    scopus 로고
    • Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma
    • PMID:20842054
    • Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33:828-33; PMID:20842054; http://dx.doi.org/10.1097/CJI.0b013e3181eec14c
    • (2010) J Immunother , vol.33 , pp. 828-833
    • Royal, R.E.1    Levy, C.2    Turner, K.3    Mathur, A.4    Hughes, M.5    Kammula, U.S.6    Sherry, R.M.7    Topalian, S.L.8    Yang, J.C.9    Lowy, I.10
  • 46
    • 84859158384 scopus 로고    scopus 로고
    • Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
    • PMID:22236695
    • Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12; PMID:22236695; http://dx.doi.org/10.1016/j.coi.2011.12.009
    • (2012) Curr Opin Immunol , vol.24 , pp. 207-212
    • Topalian, S.L.1    Drake, C.G.2    Pardoll, D.M.3
  • 47
    • 84858646786 scopus 로고    scopus 로고
    • Phase Ib study of ipilimumab alone or in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene (vaccine) in pancreatic cancer
    • ASCO Meeting Abstracts Jan 30
    • Le TL, Lutz E, Huang L, Onners B, Uram J, Solt S, et al. Phase Ib study of ipilimumab alone or in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene (vaccine) in pancreatic cancer. ASCO Meeting Abstracts Jan 30, 2012: 211
    • (2012) , pp. 211
    • Le, T.L.1    Lutz, E.2    Huang, L.3    Onners, B.4    Uram, J.5    Solt, S.6
  • 48
    • 84883207410 scopus 로고    scopus 로고
    • Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
    • PMID:23924790
    • Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013; 36:382-9; PMID:23924790; http://dx.doi.org/10.1097/CJI.0b013e31829fb7a2.
    • (2013) J Immunother , vol.36 , pp. 382-389
    • Le, D.T.1    Lutz, E.2    Uram, J.N.3    Sugar, E.A.4    Onners, B.5    Solt, S.6    Zheng, L.7    Diaz Jr., L.A.8    Donehower, R.C.9    Jaffee, E.M.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.